Click on any of the studies below to learn more about whether you might be eligible to participate and contact our research team.
The purpose of this trial is to study whether daily administration of Cannabidiol (CBD) versus placebo for 4-months can help reduce opioid use and pain in people suffering from chronic spinal radicular (i.e., pinched nerve in spinal cord) pain conditions, who are maintained on opioid pain medications, and who are motivated to decrease their opioid analgesic maintenance dose.
The purpose of this research study is to see how safe and effective Methylenedioxymethamphetamine (MDMA) is for the treatment of post-traumatic stress disorder (PTSD). MDMA is currently an experimental medication and has not been approved as a safe or effective treatment for any health condition.
This study, sponsored by the Multidisciplinary Association for Psychedelic Studies, is a Phase 3 study intended to provide evidence of safety and efficacy that will be submitted to the United States Food and Drug Administration (FDA) as part of an application to permit the use of MDMA as a treatment for PTSD. Participants in the study receive MDMA or placebo in three experimental sessions, together with a total of 12 non-drug psychotherapy sessions. MDMA causes release of serotonin and other neurotransmitters in the brain, which is thought to alter the way people think and feel about traumatic experiences they have had.
Interested in participating in a future research study at the Center for Psychedelic Medicine? Please click this link to provide your contact information as well as answer a few questions about yourself and types of studies you may be interested in. If the information you provide indicates that you might qualify for a clinical research study within in the Center for Psychedelic Medicine, a study team member will follow up with you by your preferred contact method.